COVID-19 Induced Pancytopenia in a Major Molecular Response CML patient on Dasatinib: A Case Report and Review of Literature

  • Balraj Singh Department of Hematology & Oncology, Saint Joseph's University Medical Center, Paterson, NJ, USA https://orcid.org/0000-0001-7986-6031
  • Sarah Ayad Department of Hematology & Oncology, Saint Joseph's University Medical Center, Paterson, NJ, USA
  • Parminder Kaur Department of Cardiology, Saint Joseph's University Medical Center, Paterson, NJ, USA
  • Vinod Kumar Department of Hematology & Oncology, Saint Joseph's University Medical Center, Paterson, NJ, USA
  • Sachin Gupta Department of Internal Medicine, Tower Health Reading Hospital, West Reading, PA, USA
  • Michael Maroules Department of Hematology & Oncology, Saint Joseph's University Medical Center, Paterson, NJ, USA

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), has caused a global health crisis. COVID-19 can have a multifaceted presentation. A wide range of complications and outcomes can emerge based on the severity and comorbidities of the infected patient.  We report a 42-year-old male with past medical history of CML on Dasatinib (in Major Molecular Response) who was diagnosed with COVID-19 and developed pancytopenia. Our case and review of available reports add to the limited literature available regarding COVID-19 in CML.

VIEW THE ENTIRE ARTICLE

References

  • Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med 2020;26(7):1017–1032.
  • Sorà F, Chiusolo P, Laurenti L, Innocenti I, Autore F, Alma E, et al. SARS CoV 2 infection in chronic myelogenous leukemia: severe hematological presentation. Transfus Apher Sci 2020;59(6):102881.
  • Eden RE, Coviello JM. Chronic myelogenous leukemia. Treasure Island (FL): StatPearls Publishing; 2020.
  • Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21(3):335–337.
  • Abruzzese E, Luciano L, D'Agostino F, Trawinska MM, Pane F, De Fabritiis P. SARS-CoV-2 (COVID-19) and chronic myeloid leukemia (CML): a case report and review of ABL kinase involvement in viral infection. Mediterr J Hematol Infect Dis 2020;12(1):e2020031.
  • Lagziel T, Quiroga L, Ramos M, Hultman CS, Asif M. Two false negative test results in a symptomatic patient with a confirmed case of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and suspected Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). Cureus 2020;12(5):e8198.
  • Li W, Wang D, Guo J, Yuan G, Yang Z, Gale RP, et al. COVID-19 in persons with chronic myeloid leukaemia. Leukemia 2020;34(7):1799–1804.
  • Ector G, Huijskens EGW, Blijlevens NMA, Westerweel PE. Prevalence of COVID-19 diagnosis in Dutch CML patients during the 2020 SARS-CoV2 pandemic. A prospective cohort study. Leukemia 2020;34(9):2533–2535.
  • Breccia M, Abruzzese E, Bocchia M, Bonifacio M, Castagnetti F, Fava C, et al. Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A Campus CML survey. Leukemia 2020;34(8):2260–2261.
  • Ba?c? S, Ata N, Altunta? F, Yi?eno?lu TN, Dal MS, Korkmaz S, et al. Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors. J Oncol Pharm Pract 2020;26(7):1676–1682.
  • Paul TR, Uppin SG, Uppin MS, Jacob RT, Rao DR, Rajappa SJ. Evaluation of cytopenias occurring in imatinib treated chronic myeloid leukemia (CML) patients. Indian J Hematol Blood Transfus 2010;26(2):56–61.
  • E?kazan AE. Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities—which TKI is the safest? Br J Clin Pharmacol 2019;85(10):2241–2243.
  • Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother 2014;58(8):4885–4893.
  • Galimberti S, Petrini M, Baratè C, Ricci F, Balducci S, Grassi S, et al. Tyrosine kinase inhibitors play an antiviral action in patients affected by chronic myeloid leukemia: a possible model supporting their use in the fight against SARS-CoV-2. Front Oncol 2020;10(1428).
  • Rizzo AN, Sammani S, Esquinca AE, Jacobson JR, Garcia JGN, Letsiou E, et al. Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury. Am J Physiol Lung Cell Mol Physiol 2015;309(11):L1294–L304.
  • Published: 2021-01-12

    Issue: 2021: Vol 8 No 1 (view)

    Section: Articles

    How to cite:
    1.
    Singh B, Ayad S, Kaur P, Kumar V, Gupta S, Maroules M. COVID-19 Induced Pancytopenia in a Major Molecular Response CML patient on Dasatinib: A Case Report and Review of Literature . EJCRIM 2021;8 doi:10.12890/2021_002233.

    Most read articles by the same author(s)